Glycosylated Hemoglobin and Risk of Perioperative Major Cardiovascular Events in Diabetic Patients Undergoing Coronary Bypass Revascularization (HbA1c)
Glycosylated Hemoglobin and the Risk of Perioperative Major Cardiovascular Events in Diabetic Patients Undergoing Coronary Bypass Revascularization
1 other identifier
observational
589
1 country
1
Brief Summary
Glycosylated Hemoglobin (HbA1c) is considered as one of the best markers to assess the glycaemia treatment over a period of 3 to 4 months, and is considered as predictive marker for perioperative mortality and morbidity. The impact of the elevated HbA1c on the risk of perioperative major cardiovascular events in patients undergoing coronary bypass revascularization (by retrospective analysis of perioperative cardiovascular events and preoperative HbA1c) is evaluated.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2017
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 29, 2017
CompletedFirst Submitted
Initial submission to the registry
July 4, 2018
CompletedFirst Posted
Study publicly available on registry
July 18, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 21, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
August 21, 2018
CompletedApril 1, 2021
March 1, 2021
8 months
July 4, 2018
March 29, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
occurence of Major adverse cardiac events
myocardial infarction, cardiac related death, stroke
perioperative = in hospital
Secondary Outcomes (3)
occurence of severe renal insufficiency
perioperative = in hospital
occurence of sternal wound infection
perioperative = in hospital
mortality
perioperative = in hospital
Interventions
analysis of perioperative major cardiovascular events in diabetic patients
Eligibility Criteria
all patients with diabetes mellitus * undergoing coronary bypass revascularization at the Klinik für Herzchirurgie, Universitätsspital Basel, Spitalstrasse 21, CH 4031-Basel since 2012 * who did not disapprove of use of data for research purposes * statistic stratification in serum level of glycosylated hemoglobin (HbA1c) \> 6.5% and \</= 6.5%
You may qualify if:
- patients with Diabetes mellitus undergoing coronary bypass revascularization since 2012
You may not qualify if:
- disapproval of use of data for research purposes
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Herzchirurgie University Hospital Basel
Basel, 4031, Switzerland
Related Publications (1)
https://www.pulsus.com/scholarly-articles/glycosylated-hemoglobin-and-adverse-events-following-elective-coronary-bypass-revascularization-4682.html
RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Denis Berdajs, PD Dr. med
University Hospital, Basel, Switzerland
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 4, 2018
First Posted
July 18, 2018
Study Start
December 29, 2017
Primary Completion
August 21, 2018
Study Completion
August 21, 2018
Last Updated
April 1, 2021
Record last verified: 2021-03